Table 1.

Median values of sPDL1 or change in sPDL1 (pg/mL) for patient cohorts in CM-009 and CM-038-P1

Trial	Cohort	Baseline (n=)	Baseline (pg/mL)	Day 29 (pg/mL)	Day 43 or 63 (pg/mL)	Baseline to day 29 (paired samples n=)	Baseline to day 29 (change in pg/mL)	Baseline to day 43 or 63 (paired samples, n=)	Baseline to day 43 or 63 (change in pg/mL)
RCC CM-009	Trial cohort	91	1978	2300	2179	79	180	63	114
	2+L cohort	67	2057	2374	2332	57	185	42	95
	PD	27	3138	3397	4043	25	259	14	224
	SD	42	1809	1999	1866	38	103	35	134
	CRPR	14	1635	2115	1692	14	42	13	−83
Melanoma CM-038	Trial cohort	78	2312	2361	2247	63	175	58	171
	PD	34	2183	2065	2238	27	175	22	243
	SD	24	2452	2654	2505	21	188	19	160
	CRPR	20	1936	1970	2133	15	79	17	70

Samples with imputed values are included in calculation of the time point-specific medians, but are not included in any analyses of change over time. The second time point is day 63 in CM-009 and day 43 in CM-038-P1.

CRPR, complete or partial response; PD, progressive disease; RCC, renal cell carcinoma; SD, stable disease.